Vaishali Sanchorawala MD
Professor, Hematology & Medical Oncology
Associate Director, Amyloidosis Center
72 E. Concord Street | (617) 358-4750vaishali.sanchorawala@bmc.org
vsanchor@bu.edu
Sections
Hematology & Medical Oncology
Centers
BU-BMC Cancer Center
Amyloidosis Center
Biography
72 East Concord Street, K-503, Boston, MA 02118
820 Harrison Avenue, Boston, MA 02118 (clinic address)
Expertise includes: AL amyloidosis - clinical trials, treatment; Amyloidosis; Stem cell transplantation; Myeloma.
Dr Vaishali Sanchorawala is the Director of Stem Cell Transplantation program at Boston Medical Center; Director of Amyloidosis Center at Chobanian and Avedisian School of Medicine; Skinner Professor of Amyloidosis Research in the Department of Medicine; Associate Editor of Amyloid: The Journal of Protein Folding Disorders and Secretary of the International Society of Amyloidosis for the term 2020-2022.
Her research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she is one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has resulted in the evolution of the standard of care for these patients. I am currently heading several clinical trials in the treatment of AL amyloidosis, two of which were conducted nationally through the Southwest Oncology Group (SWOG0115 and SWOG1702), completed accrual in a timely fashion and led to publications in a peer-reviewed journals.
Dr Sanchorawala is part of the faculty at major international conferences in amyloidosis and has given many invited talks at national and international meetings. She is active in various non-profit organizations, regulatory authorities, and funding bodies as an expert on amyloidosis. She is at present a member of the Executive Steering Committee of Amyloidosis Research Consortium which is developing pathways to education, patient voice, development of treatment and access to novel therapies. She has participated in meetings with the FDA for enhancing the amyloidosis drug development pathway, guidance for more efficient and successful programs. She serves on the advisory board of number of leading pharmaceutical partners for drugs in AL amyloidosis.
She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis. She regularly attends a number of patient information seminars and support group meetings in the US. She also created the first “live tweet event” for patients and care givers to ask questions via social media.
Outside of roles of direct research and clinical care, she has an interest inworking in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteers regularly at “Cradles to Crayons” charity, non-profit organization.
Other Positions
Education
MBBS, Seth G.S. Medical College
Publications
Azzam M, Hamarsha Q, Kawtharany H, Nazzal J, Alkhader A, Khraise T, AlMasri MM, Abou Zeid HK, Alwan I, Jaber N, Seftel MD, Aguirre MA, Boedicker D, Bumma N, Carroll A, Comenzo R, Cook J, Dasgupta N, De La Torre AH, Dispenzieri A, Jamal F, Khouri J, Picken MM, Raza S, Leung N, Sanchorawala V, Sarswat N, Shaikh H, Singh D, Kukreti V, Mustafa RA. Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis. Blood Adv. 2026 Aug 11; 10(15):5293-5307. PMID: 41979328.
Published on 8/3/2026Wechalekar AD, Dispenzieri A, Sanchorawala V, Kastritis E, Bhutani D, Bianchi G, Jimenez-Zepeda VH, Suzuki K, Lentzsch S, Huart A, Carpinteiro A, Swenson ES, Khan Z, Catini J, Kulkarni H, Meltzer B, Lake S, Liedtke M. Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials. J Clin Oncol. 2026 Aug 03; JCO2601665. PMID: 42546230.
Published on 7/28/2026Kukreti V, Seftel M, Aguirre MA, Azzam M, Boedicker DD, Bumma N, Carroll AS, Comenzo R, Cook J, Dasgupta N, De La Torre A, Dispenzieri A, Jamal F, Kawtharany H, Khouri J, Leung N, Nazzal J, Picken MM, Raza S, Sanchorawala V, Sarswat N, Shaikh H, Singh D, Mustafa RA. American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis. Blood Adv. 2026 Jul 28; 10(14):5113-5152. PMID: 41592868.
Published on 7/20/2026Alqazaqi R, Taasan S, Schwartzman W, Khan AM, Afrough A, Zahid MF, Schinke C, van Rhee F, Anderson LD, Sanchorawala V, Al Hadidi S. Efficacy and Safety of BCMA-Targeted Therapies in Relapsed or Refractory AL Amyloidosis: A Descriptive Pooled Analysis. Blood Adv. 2026 Jul 20. PMID: 42478693.
Published on 7/14/2026Berumen A, Staron A, Kalaitzidis G, Siddiqi OK, Gopal DM, Ruberg FL, Sanchorawala V. Evaluating AL-ISS within a BNP-based model for AL amyloidosis in the daratumumab era. Blood Adv. 2026 Jul 14; 10(13):4612-4616. PMID: 41995749.
Published on 7/8/2026Bianchi G, Sanchorawala V, Wechalekar A, Grogan M, Cuddy SAM, Merlini G. Systemic light chain and transthyretin amyloidosis-treatment advancements and future directions. Lancet. 2026 Aug 01; 408(10553):471-487. PMID: 42419329.
Published on 6/24/2026Prokaeva T, Jayaraman S, Klimtchuk ES, Libbey C, Mendelson L, Spencer B, Chen H, Van Le NH, Sanchez A, Kelleher NL, Dasari S, McPhail ED, Pereira L, Avissar U, Cerda S, Wong S, Lavatelli F, Sanchorawala V, Gursky O. Structural Basis for the Pro-amyloidogenic Action and Ligand Binding of a Novel W72R Variant of Human Apolipoprotein A-I. J Mol Biol. 2026 Jun 24; 438(19):169916. PMID: 42341910.
Published on 5/29/2026Wechalekar AD, Dispenzieri A, Sanchorawala V, Kastritis E, Bhutani D, Bianchi G, Jimenez-Zepeda VH, Suzuki K, Lentzsch S, Huart A, Carpinteiro A, Swenson ES, Khan Z, Catini J, Kulkarni H, Meltzer B, Lake S, Liedtke M. Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials. J Clin Oncol. 2026 Jul 10; 44(20):1899-1910. PMID: 42212672.
Published on 5/12/2026Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Mollee P, Lu J, Schönland SO, Gatt ME, Suzuki K, Kim K, Cibeira MT, Bhutani M, Beksac M, Libby EN, Valent J, Hungria V, Rosenzweig MA, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman A, Goodman S, Zonder JA, Lam S, Song KW, Hansen T, Manier S, Roeloffzen WWH, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoé EQ, Tran N, Wang J, Chen Y, Vasey SY, Schecter JM, Vermeulen J, Comenzo R, Merlini G. Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis. Blood. 2026 May 12. PMID: 42118698.
Published on 4/15/2026Sanchorawala V, Greatsinger A, Staron A, Berk JL, Mendelson LM, Joshi T, J Burke N, Tabatabaeepour N, Smith J, Signorovitch J. Disease burden of ATTR amyloidosis based on the SF-36® health survey. Cardiooncology. 2026 Apr 15; 12(1). PMID: 41987333.
Media Mentions
Published on 10/13/2024
New study underway in Boston for people with advanced stage of AL amyloidosis
Published on 6/27/2024
: Early diagnosis key in combating the deadly effects of AL amyloidosis
Published on 6/27/2024
Early diagnosis key in combating the deadly effects of AL amyloidosis
Published on 6/26/2024
Published on 6/26/2024
Published on 9/22/2022
There’s New Proof Crispr Can Edit Genes Inside Human Bodies
Published on 8/5/2022
Young Black Patients With AML Face Significantly Worse Outcomes
Published on 7/20/2022
Stem Cell Transplantation Shows Promise in AL Amyloidosis
Published on 7/14/2022
Published on 7/14/2022
View full list of 15 media mentions.